1Department of Tumor Biology,
Correspondence Address: Ass. Prof. Heidi Schwarzenbach, Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg 20246, Germany. E-mail: email@example.com
© The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Initially, most ovarian tumors respond to the treatment with platinum components, but frequently recurrence occurs within the following two years in advanced ovarian cancer patients. In this regard, previous studies have shown changes in the epigenetic patterns in ovarian cancer that are linked with resistance to cis- and carboplatin therapy. Thus, epigenetic changes mediated by a treatment with cis- or carboplatin could identify such patients who do or do not respond to this therapy. Therefore, an understanding of the impact of platinum on epigenetics in ovarian cancer is important in overcoming platinum resistance. In this review, we delineate epigenetic abnormalities in cis- and carboplatin-resistant ovarian tumors, such as changes in DNA methylation, histone modifications and deregulation of microRNAs, and discuss the potential of epigenetic therapies in combination with platinum.
Ovarian cancer, carboplatin, cisplatin, resistance, DNA methylation, histone modifications, microRNAs
Although ovarian cancer is a leading cause of gynaecological cancer deaths, the primary cause of the disease remains unclear. The lack of early markers of ovarian cancer and the development of drug resistance following chemotherapy with, e.g., platinum-based compounds retards attempts to better identify and treat this cancer.
In 1896, Baldwin postulated that individuals within a population with the “correct” allele could choose a new environment so resulting in a permanently changed evolutionary development within that environment. It is now more than 60 years since Waddington[2,3], following up this approach, introduced the term “epigenetics” to describe the concept that a characteristic acquired within a total population as a response to an environmental stimulus could be inherited in the absence of DNA mutations. For example phenotypic modifications can occur through the alteration of gene expression without any modification to the DNA sequence of the gene itself. Although the concept was not readily accepted at the time, epigenetics has subsequently become an important aspect of genetics and evolutionary theory, and is of particular interest in the study of cancer initiation, development and possible resolutions.
Specifically, epigenetic modifications involve DNA methylation, nucleosome repositioning, histone post-translational modifications and post-transcriptional gene regulation by miRNAs. Histone modifications can affect chromatin structure resulting in the passage of heritable changes to the next generation. The role of histone epigenetic modifications in ovarian cancer has been comprehensively considered in a review by Yang et al.. Although they have compiled an impressive listing of histone modifications, they considered that such studies are only at an early stage. Nevertheless, there are a number of epigenetic inhibitors being considered with protein modifying drugs already under clinical trials for ovarian cancers. Currently, there appears to be a low specificity for such compounds.
The major form of treatment for ovarian cancers, evolved from earlier studies on the use of platinum compounds inhibiting Escherichia coli cell division and solid tumors involves the use of platinum containing molecules[6,7]. A range of such compounds has been developed namely, cisplatin, carboplatin, oxaliplatin, nedaplatin and lobaplatin, the most commonly used for ovarian cancer treatment being cisplatin and carboplatin.
In the present review, we will examine DNA methylation and their involvement in the different forms of ovarian cancer together with the epigenetics of both histones and miRNAs and their possible roles concerning the reversal of resistance to cis- and carboplatin in ovarian cancer treatment.
Similarities between the early stages of normal embryological development and cancer development have been noted since before the mid 20th century. Epigenetic alterations involving DNA methylation can be considered as such an example, DNA methylation being a basic step essential to the early stages of embryogenesis. However, cancer initiation also involves alterations of DNA methylation in the silencing of tumor suppressor genes, the activation of oncogenes and the initiation of metastases. In particular, aberrant DNA methylation in cancer can be directly linked to drug resistance.
DNA methylation normally occurs on the cytosine residues adjacent to a guanine residue (CG dinucleotides), the methyl group from S-adenosylmethionine being attached to cytosine by DNA methyltransferase. Thus, DNA modification involves 5-methylcytosine, 5-formylcytosine, 5-hydroxymethylcytosine and 5-carboxylcytosine. The CG residues may be present singly along the DNA strands and tend to be constantly methylated. Alternatively, they may be present in clusters of 1000-2000 residues along the DNA in the form of CpG islands that are associated with gene promoters. Hence, if hypomethylated, the genes are active and if hypermethylated, the genes are silenced. In many cancers, including ovarian cancer, a decrease in the global methylation of the heterochromatic chromosome regions results in the activation of a number of oncogenes, whilst the locus-specific hypermethylation of specific CpG island regions associated with promoters of tumor suppressor genes results in their inactivation[4,11-13]. Nevertheless, when methylation occurs, there are cases when only one allele maybe methylated and the other not. Hence, it depends on which allele is expressed as to the expression outcome, e.g., this can occur in ovarian cancer[14,15]. Gene expression by the non-methylated allele is likely for some genes so leading to continued expression despite the other allele being methylated. In their study, Losi et al. investigated 41 ovarian cancer associated promotor genes, and observed an intermediate level of hypermethylation (~50%) for most hypermethylated genes. Since there were > 70% of tumor cells present in each tumor sample employed, they would have expected either a high or a low methylation level. Combining their data with those described in the literature, where most studies dealt with very few genes, they proposed that this might be a general event of intra-tumoral heterogeneity existing for epigenetic changes.
Hypermethylation also has its effects with that of promoter CpG islands causing the silencing of tumor suppressor genes whilst methylation of CpG islands results in the inhibition of transcription factor suppressors.
Gene selection is also important for the study of ovarian cancer. Whilst Losi et al. and Choi et al. listed genes involved in cancer in general those epigenetically modifiable promoter genes relevant to ovarian cancer are given in Table 1. Genes involved in cisplatin/carboplatin resistance/sensitization of ovarian cancer are presented in Table 2.
Epigenetically modifiable promoter genes relevant to ovarian cancer
|DNA methylation||APC, ESR, MGMT, RASSF1A, MLH1, TERT, WT1|
|Testis/ovarian cells||BORIS/CTCFL, DAX1, FOXL2, RSPO1, TMEFF2|
|Wnt pathway||APC, DKK1, DKK2, DKK3, SFRP1, SFRP4, SFRP5, WIF1, WNT4|
|DNA repair pathways||BRCA1, MGMT, MLH1|
Epigenetically modifiable genes relevant to ovarian cancer resistance and sensitization to cisplatin/carboplatin
|Cisplatin resistance||OXCT1, GPCR, TET1, MLH1[21-23], HOXA10, HOXA11[21,24], NAGA, UCHL1, BCL2L1, FANCF[28-30]|
|Cisplatin sensitization||FANCF, NAGA, CCDC69, UCHL1|
|Carboplatin Resistance||TMEM88, DOK2[34,35], p57(Kip2), Plk2, HERV-K, SFRP5, SLFN11, ASS1|
Finally, it appears to be necessary to consider the effect of the degree of methylation of each gene with respect to the histological type of ovarian cancer being investigated, e.g., epithelial, serous, endometrioid and mucinous since each may offer a different response depending upon the degree of methylation of a particular gene.
When determining methylation levels, there are a number of approaches. The first consideration concerns tissue preparation before selection of that which is to be analysed. Thus, the tissue may be either histologically processed, often wax embedded or, alternatively, the tissue may be either as fixed or unfixed, frozen sections. The selected material to be analysed is isolated from the sections after microscopical analysis. Hence, there are three different factors involved relating to the tissue sample examined, namely, chemical fixation of the tissue, dewaxing of embedded material and the use of unfixed, frozen tissue.
Once the selected material has been removed from the sections, a relevant method for analysis of methylation levels needs to be selected. Some methods utilized for the detection of DNA methylation levels[42-45]: Digestion-based assay (PCR, qPCR, RT-PCR, cold PCR); High resolution melting luminometric methylation assay; HPLC-UV; Mass spectrometry; ELISA-based methods; Amplified fragment length polymorphism; Restriction fragment length polymorphism; Luminometric methylation assay; Pyrosequencing; Bisulfite sequencing; ELISA; Methylation ligation-dependent macro-array; High-throughput measurement technologies.
An in-depth analysis of the majority of the available methods was given by Olkhov- Olkhov-Mitsel & Bapat to detect methylated and hydroxyl-methylated DNA biomarkers. The methods are grouped under bisulphite-based strategies, restriction enzyme based methods and affinity-based strategies. Subsequently, Kurdyukov and Bullock developed a simple algorithm for selecting the most appropriate method for the material to be analyzed and for the identification of the form of methylation to be determined through either whole genome methylation profiling or identification of differentially-methylated regions or the methylation status of specific genes or digestion based assays or differentially-methylated loci or hydroxymethyl cytosine determination.
Clearly, given the range of methods available for the determination of different aspects of DNA methylation used by different authors, it becomes somewhat difficult to routinely compare results in the case of applied topics, such as ovarian cancer.
Using the various methods available, a number of abnormal DNA methylation patterns have been demonstrated in cancer cells with specific consequences being identified. Hence, global hypomethylation can lead to chromosomal and genetic instability as well as reactivation of endoparasitic and repetitive genomic sequences. In addition, hypomethylation of gene bodies can activate incorrect sites of transcription initiation while the loss of promoter methylation can cause activation of metastasis and tumor promoting genes.
Epithelial-mesenchymal transition (EMT) is a hallmark of cancer progression and metastasis. During this process, epithelial cells go through phenotypic changes and acquire mesenchymal characteristics. They lose their cell polarity and cell-cell adhesion and acquire migratory and invasive properties, facilitating their migration through the extracellular matrix and settlement in other organs. This molecular reprogramming and cell switch lead to the loss of cytokeratins and epithelial-specific junction proteins, e.g., E-cadherin, mediated by upregulation of the transcriptional repressors Snail and Slug, ZEB1 and ZEB2, and Twist, and turning on the expression of mesenchymal markers e.g. Vimentin and N-cadherin. EMT is induced by a variety of signals, including the Wnt/β-catenin signaling pathway, Notch transcription factors, phosphoinositide-3 kinase (PI 3K)/Akt signaling.
The following paragraphs contain a short overview on the signaling pathways most frequently involved in platinum resistance.
The Wnt signaling pathway is a complex developmental cell signaling pathway which plays an essential role in embryogenesis. The network is generally divided into the β-catenin dependent (canonical) and the β-catenin independent (non-canonical) pathways. Wnt proteins bind to receptors of the Frizzled and the low-density lipoprotein receptor-related protein families on the cell surface. Through several cytoplasmic components, the signal is transmitted to β-catenin which then enters the nucleus and forms a complex with the transcription factor TCF to activate transcription of Wnt target genes. The activation of the pathway leads to a variety of biological processes, including cell proliferation, differentiation and migration. Aberrant oncogenic activation of the Wnt signaling pathway is a common event in different cancer types. Main mechanisms by which Wnt signaling is dysregulated in cancer are mutations in β-catenin or other key pathway members, as well as hypermethylation and silencing of gatekeeper antagonists, such as the secreted frizzled-related protein (SFRP) and dickkopf (DKK), or overexpression of Wnt ligands or receptors, resulting in increased cancer cell proliferation and migration.
The activation of PI3K/Akt pathway regulates many different physiological processes, such as transcription, protein synthesis, metabolic responses and membrane trafficking, and specifically promotes growth and proliferation of adult stem cells. There are many factors that boost the PI3K/AKT pathway, including EGF, IGF-1 and insulin. Activation of PI3K phosphorylates and activates AKT, localizing it in the plasma membrane. AKT has diverse downstream effects, among others activating CREB, inhibiting p27 and activating mTOR (mammalian target of rapamycin). The pathway is antagonized by PTEN (phosphatase and tensin homologue). In many cancer types, this pathway is abnormally activated, resulting in reducing apoptosis and allowing proliferation.
Depending on the cellular context, the Notch pathway regulates proliferation, differentiation and apoptosis. In adult tissues, Notch signaling is involved in tissue homeostasis and stem cell maintenance. The Notch signaling pathway also plays an established role in embryologic development and its deregulation is associated with diverse cancer types. It is activated by a receptor-ligand binding between two neighboring cells, leading to a conformational change of the Notch receptor. Following two cleavages, the Notch intracellular domain (NICD) is released into the cytoplasm. After translocation into the nucleus, NICD binds to ubiquitous transcription factor CSL and converts a large co-repressor complex into a transcription activating complex. The complex activates the transcription of Notch target genes, among others p21, cyclin D1 and 3, c-myc and members of NF-κB family.
The origin of platinum-cancer therapy dates back to the year 1965, when it was reported that cisplatin is an inhibitor of cell division in Escherichia coli. In 1970, it was shown that cisplatin inhibits the growth of large tumors, possibly by inhibition of DNA synthesis. Currently, cisplatin is one of the most effective chemotherapeutic agents and used for several tumor types. However, its clinical use is limited due to the severe side effects, including nephrotoxicity and acute kidney injury. Carboplatin has been established as the successor to cisplatin with improved tolerability in many therapeutic regimens. This second generation analogue is closely related to cisplatin. Both cisplatin and carboplatin are the primary first-line therapies for the treatment of ovarian cancer. They are hydrolyzed in the cell, reacting with the sulfhydryl groups of proteins and nitrogen atoms of nucleic acids. Their covalent binding with purine bases introduces DNA damage, such as monoadducts or inter- and intra-strand crosslinks resulting in interference of the replication machinery, G2/M cell arrest and cell death by apoptosis or necrosis [Figure 1]. They can also induce oxidative stress by increasing mitochondrial reactive oxygen species and decreasing intracellular antioxidants, like reduced glutathione (GSH).
Figure 1. Chemical structures of cis- and carboplatin (A). Action of platinium. Cisplatin [Cis-diamminedichloroplatinum (II)] forms intracellular electrophilic water complexes based on the commonly predominant lower chloride concentrations. Due to its high affinity to the bases guanine and adenine, it forms chelates and inhibits DNA expression. Crosslinks of the DNA single and double strands are formed by platination with a disorder of template function and cell division. Carboplatin [Cis-Diamin (1,1cyclobutandicarboxylo)-platinium] has an equivalent mechanism of action. Chelation and cross-linking of the single and double-stranded DNA inhibit DNA synthesis and transcription triggering apoptosis (B)
Acquired platinum resistance is considered as a multi-factorial process. Numerous mechanisms leading to the development of drug resistance have been reported and comprehensively considered. They include e.g., changes in drug efflux through the modulation of diverse transporter systems, deregulated levels of intracellular glutathione and metallothioneine able to bind and sequester platinum, altered DNA repair pathways and reduced expression of pro-apoptotic proteins. These modulations are associated with epigenetic changes in DNA methylation, histone modifications and microRNA levels, but also with genetic alterations, such as mutations or deletion[52,54]. In this section, we present a short overview of the main mechanisms of cis- and carboplatin resistance to better illustrate the impact of these drugs on epigenetics in the following sections.
Cis- and carboplatin enter the cells and are exported from cells via transporters that e.g., manage copper homeostasis. The major copper influx transporter, copper transporter 1 (CTR1), controls the tumor cell accumulation and cytotoxic effect of cisplatin and carboplatin. Both copper and cisplatin may trigger the down-regulation of CTR1 via a process that involves ubiquitination and proteosomal degradation. In this regard, the majority of cells with acquired resistance to platinum drugs exhibit reduced drug accumulation. Thus, the cytotoxicity of these drugs correlates with the amounts of drugs entering the cell[55,56].
Furthermore, oxidative stress is the one of most important mechanisms involved in cisplatin toxicity. Under normal physiological conditions, cells control reactive oxygen species levels by balancing the generation of reactive oxygen species with their elimination by e.g., GSH. Hence, glutathione acts as an antioxidant in the cell and supports the redox environment while conserving reduced sulfhydryl groups. Elevated levels of glutathione and glutathione-S-transferase, an enzyme mediating cisplatin coupling to GSH, induce resistance to cisplatin. In this regard, cisplatin is detoxified by glutathione through adduct formation, and these platinum/glutathione conjugates are readily secreted out of the cells by e.g., multidrug resistance proteins of the ABC family.
Finally, platinum damage is repaired primarily by the nucleotide excision repair system and the homologous recombination pathway. The nucleotide excision repair system recognizes platinum-induced inter- and intra-strand crosslinks and induces a process of DNA unwinding, incision, excision and synthesis. Induced DNA double-strand breaks are recognized by homologous recombination repair which initiates a process of single strand DNA formation, coating, filament formation, strand invasion and DNA synthesis. In particular, excision repair cross complementation group-1 and the related genes XPA and BRCA1 are involved in DNA repair. For example, 50% of high-grade serous ovarian cancers (HGSOC) exhibit defective DNA repair by inactivation of the homologous recombination due to germline and somatic mutations in BRCA1 (11%), BRCA2 (9%) and promoter hypermethylation of BRCA1 (10%). Homologous recombination deficiency may also result from PTEN homozygous loss, detected in about 7% of HGSOC.
Epigenetic gene silencing is increasingly being recognized to contribute to the development of cis- and carboplatin resistance. Auspiciously, the treatment with demethylating agents has been shown to re-sensitize patients to platinum therapy demonstrating that DNA methylation is a critical factor in drug resistance. The most important DNA methyltransferase (DNMT) inhibitors are azacitidine and decitabine (5-aza-2′-deoxycytidine, dacogen). They are hypomethylating analogues of cytidine [Figure 2], and commonly used to treat myelodysplastic, hematological malignancies. Azacitidine was the first drug to demonstrate a survival benefit in a randomized trial for patients with myelodysplastic syndromes[60,61]. The following paragraphs give an overview on methylated genes that affect chemo-resistance.
Figure 2. Chemical structures of azacitidine and decitabine. Azacitidine is metabolized intracellularly into decitabine
In ovarian cancer, selective epigenetic alterations of distinct biological pathways have been observed during development of platinum resistance. Hypermethylation-mediated repression of cell adhesion and tight junction pathways as well as hypomethylation-mediated activation of the cell growth-promoting pathways PI3K/Akt and TGF-β may contribute to platinum resistance. As the following in vitro and in vivo studies demonstrate, chemo-resistance may be reversible by alteration of DNA methylation which may be an effective strategy to enhance the effectiveness of chemotherapeutic treatment in ovarian cancer.
High expression of DNMT1 is detected in S-phase of the cell cycle and makes DNMT1 a specific target for DNA methylation inhibition in rapidly dividing cancer cells. Covalent binding of DNMT1 by the nucleoside analogue SGI-110 results in DNMT1 proteolysis. To assess the effects of SGI-110 on chemo-responsive genes silenced by DNA methylation in ovarian cancer, Fang et al. applied pyrosequencing. In vitro, they demonstrated that SGI-110 re-sensitized a range of cisplatin-resistant ovarian cancer cells, and induced significant demethylation and re-expression of tumor suppressor genes, differentiation-associated genes and even, putative drivers of ovarian cancer cisplatin resistance. In vivo, pyrosequencing of ovarian cancer xenografts confirmed that SGI-110 caused both global (LINE1 repetitive sequences) and gene-specific hypomethylation, including the tumor suppressor gene Ras Association Domain Family 1 (RASSF1A), the assumed drivers of ovarian cancer cisplatin resistance and the zinc finger protein ZIC1, the differentiation-associated genes HOXA10 and HOXA11 and the transcription factor STAT5B, as well as the DNA mismatch repair gene MLH1. The methylation of MLH1 in resistant cells has been investigated by several laboratories. Using genome-wide DNA methylation profiling, Zeller et al. identified genes becoming hypermethylated in chemo-resistant ovarian cancer cells. In particular, they found that MLH1 had a direct role in conferring cisplatin sensitivity when reintroduced into cells in vitro. These findings supported previous observations from Strathdee et al., 20 years ago. DNMT activity and thus, DNA methylation are regulated by the epidermal growth factor receptor (EGFR). Granados et al. examined whether cisplatin induces EGFR mediated changes in DNA methylation that are associated with the development of cisplatin resistance. Acute cisplatin treatment activated EGFR and downstream signaling pathways, as well as induced an EGFR-mediated increase in DNMT activity. This led to an increase in global DNA methylation in cisplatin resistant cells. During repeated cisplatin treatments, EGFR inhibition re-sensitized the cells to cisplatin and inhibited increases in DNA methylation and DNMT activity.
The ten-eleven translocation (TET) family of dioxygenases comprising TET1/2/3 is involved in DNA demethylation. Using cisplatin-sensitive and cisplatin-resistant ovarian cancer cell models, Han et al. detected that TET1 was significantly upregulated in cisplatin-resistant ovarian cancer cells compared with cisplatin-sensitive cells. Its ectopic cell expression promoted cisplatin resistance and decreased cytotoxicity induced by cisplatin via active DNA demethylation of vimentin, resulting in partial EMT.
Applying Illumina human methylation arrays and Affymetrix arrays, Bonito et al. showed that CpG sites within the homeobox transcription factor MSX1 gene had significantly lower levels of methylation in high-grade serous epithelial ovarian cancer patients who recurred by 6 months than patients who recurred after 12 months. In cisplatin-resistant ovarian cancer cell lines, MSX1 overexpression led to cisplatin sensitization, increased apoptosis and increased cisplatin-induced expression of the cyclin-dependent kinase (CDK) inhibitor p21. A further CDK inhibitor of cell cycle progression is p27, also known as KIP1. Zhao et al. detected that the expression level of p27 was dramatically downregulated in chemo-resistant cells, but treatment with the demethylating agent 5-aza-2'-deoxycytidine restored p27 expression in cisplatin resistant cells and increased sensitivity to cisplatin. Overexpression of p27 arrested the cell in the S phase and promoted an apoptotic response to cisplatin.
To analyze genome-wide DNA methylation profiles of cisplatin sensitive and resistant ovarian cancer cell lines, Yu et al. applied methyl-Capture sequencing (MethylCap-seq), which combines precipitation of methylated DNA by the recombinant methyl-CpG binding domain of MBD2 protein with next generation sequencing (NGS). They found a lower global CpG methylation in resistant cells. Methylation-specific PCR and bisulfite sequencing confirmed hypermethylation of protein tyrosine kinase 6, protein kinase Cε and the antiapoptotic gene BCL2L1 in sensitive cells compared with resistant cells. Performing genome-wide analyses of hypermethylated CpG islands in combination with real-time PCR, Kritsch et al. identified Tribbles 2 (TRIB2) as the most pronounced downregulated gene on mRNA level among 37 commonly epigenetically silenced genes in cisplatin-resistant ovarian cancer cells. Its re-expression increased the sensitivity to cisplatin and other DNA-damaging agents in these cells, whereas its knockdown increased the resistance to cisplatin in sensitive cells. TRIB2, that belongs to the family of pseudokinase proteins and degrades the myeloid transcription factor CCAAT enhancer binding protein α, induced a cisplatin-dependent cell cycle arrest and apoptosis by acting on p21 and survivin expression. It seems to be involved in the signal transduction from nucleotide excision repair of intrastrand cross links. In line with its downregulation in ovarian cancer cells, tumors from cisplatin-resistant patients also expressed the lowest levels of TRIB2.
Using an integrated approach of analyzing simultaneously gene expression levels and DNA methylation profiles, Yang et al. analyzed mRNA expression on gene chip arrays and DNA methylation profiles on methylation bead chips. Among 26 genes that were differentially expressed and methylated between cisplatin-resistant and -sensitive ovarian cancer cells, 3-oxoacid CoA transferase 1 (OXCT1) was selected for further investigations. OXCT1, that catalyzes the first and rate-determining step of ketolysis, was hypermethylated at CpG sites of its promoter and downregulated in cisplatin-resistant cells. Treatment with a DNMT inhibitor restored hypermethylation-mediated gene silencing of OXCT1 in cisplatin-resistant cells, but not in cisplatin-sensitive cells. Notably, overexpression of OXCT1 conferred sensitivity to cisplatin in the ovarian cancer cells.
The gene encoding for myelin and lymphocyte protein (MAL) has been reported to be among the most highly expressed genes in serous ovarian cancers from short-term survivors (< 3 years) compared with those of long-term survivors (> 7 years). Lee et al. showed that this difference in MAL expression is due to differences in DNA methylation at specific sites within the MAL promoter. MAL was largely unmethylated at the transcriptional start site in serous ovarian cancers. Methylation of the region 200-400 bp upstream of the promoter could be reduced by the treatment of an ovarian cancer cell line with 5-azacytidine, resulting in a 10-fold increase in MAL expression. MAL transcript levels were also higher in cisplatin resistant ovarian cell lines suggesting that MAL methylation status serves as a marker of platinum sensitivity.
α-N-acetylgalactosaminidase (NAGA) is responsible for deglycosylating the group-specific component (Gc), a precursor of Gc protein-derived macrophage activating factor (GcMAF). The deglycosylated form of Gc protein cannot be converted into GcMAF and subsequently, decreased GcMAF levels can promote immunosuppression. Ha et al. identified NAGA as one of the key candidate genes for cisplatin drug response. In cisplatin-resistant cell lines, NAGA was significantly downregulated and hypermethylated at its promoter. Restoration and overexpression of NAGA in cisplatin-resistant lines induced cytotoxicity in response to cisplatin, whereas depletion of NAGA increased cisplatin resistance.
In their study, Cui et al. investigated coiled coil domain containing protein 69 (CCDC69), and found that its inhibition may interfere with the effectiveness of a combination therapy with platinum drugs. The expression levels of CCDC69 were 3-4 fold higher in cisplatin-resistant cells than its parental cisplatin-sensitive cells. Treatment of CCDC69 knockout, cisplatin-resistant cells with cisplatin was accompanied with increasing sensitivity to cisplatin, abrogation of G1 and G2/M arrest, increasing caspase activity, p53 acetylation and higher levels, as well as mitochondrial redistribution of the apoptosis modulator Bax.
Ubiquitin carboxyl terminal hydrolase 1 (UCHL1) catalyzes the hydrolysis of COOH-terminal ubiquityl esters and amides. Jin et al. detected UCHL1 promoter methylation in ovarian cancer cell lines and a negative correlation of UCHL1 with their cisplatin resistance. Microarray data revealed that after UCHL1 knockdown several apoptosis related genes, including apoptosis regulators BCL2, BCL11A, AEN and XIAP, and the phosphorylated serine/threonine protein kinase AKT were up-regulated, whereas the pro-apoptotic Bax was down-regulated.
FANCF (Fanconi anemia, complementation group M) is a gene associated with Fanconi anemia, the protein products of which were reported to interact with proteins involved in DNA repair pathways, e.g., with BRCA1. More than 15 years ago, Olopade and Wei described a model of ovarian cancer tumor progression that implicated aberrant FANCF promoter methylation and correlated with gene silencing and disruption of the Fanconi-anemia-BRCA pathway. Disruption of this pathway occurred de novo in ovarian cancer and might contribute to selective sensitivity to platinum components. The laboratory of D’Andrea investigated the relationship of chromosome instability with cisplatin hypersensitivity, and showed that the phenotype of ovarian cancer cells was caused by methylation and silencing of the signaling Fanconi-anemia-BRCA pathway. Restoration of this pathway was associated with demethylation of FANCF, leading to acquired cisplatin resistance. The laboratory proposed a model for ovarian tumor progression in which the initial methylation of FANCF was followed by FANCF demethylation, ultimately resulting in cisplatin resistance.
AT-101 is a natural compound from cotton seeds and inhibits the anti-apoptotic Bcl-2 family of proteins. Karaca et al. investigated the effects of AT-101 in combination with cisplatin on the expression of pro-apoptotic proteins and epigenetic events in ovarian cancer cells. Combined administration of both agents led to a strong synergistic cytotoxicity and apoptosis in human ovarian cancer cells and reduced among others Bcl-2 and inhibited both DNMT and histone deacetylase (HDAC) activities.
Applying reduced representation bisulfite sequencing, Lund et al. examined malignant ascites cells from patients with high-grade serous ovarian cancer, the most common ovarian cancer type, to clarify the molecular mechanisms of drug resistance in this cancer type. Cisplatin resistance was associated with hypomethylation at several CpG sites, primarily localized in the intergenic regions of the genome. The genes close to the differentially methylated sites were associated with canonical pathways, such as cAMP-mediated signaling, G-protein coupled receptor (GPCR) signaling, WNT/beta-catenin signaling and human embryonic stem cell pluripotency.
Several mechanisms associated with the development of acquired drug resistance in ovarian cancer have also been reported for carboplatin. Fang et al. compared the response of patients with recurrent platinum-resistant ovarian cancer who received carboplatin plus the DNMT inhibitor guadecitabine with a standard-of-care chemotherapy regimen. Epigenomic and transcriptomic profiling were performed using the Infinium methylation bead chips. They defined 94 gene promoters that were significantly hypomethylated by guadecitabine, with 1,659 genes differentially expressed in pretreatment versus post-treatment tumors resulting in altered immune reactivation and DNA repair pathways. In functional analyses, upregulation of the tumor suppressors docking protein 2 (DOK2), an adapter protein downstream of tyrosine kinase, and miR-193a silenced by promoter methylation restored platinum drug sensitivity of ovarian cancer cells. Lum et al. also characterized and functionally validated DOK2 among the genes identified in the epigenome screening using a tissue culture carboplatin resistance assay. In the set of methylated candidate genes associated with platinum resistance, the loss of DOK2 induced chemotherapy resistance by decreasing the level of apoptosis in response to the treatment. de Leon et al. used an Illumina DNA methylation array and profiled carboplatin sensitive and resistant ovarian cancer xenografts. In particular, they confirmed that the mRNA expression levels of transmembrane protein 88 (TMEM88) were increased in resistant compared to control xenografts and correlated with promoter hypomethylation. Its transcriptional regulation by promoter methylation was supported by the administration of ovarian cancer cells with the DNMT inhibitor guadecitabine which increased TMEM88 mRNA expression levels. TMEM88 knock-down re-sensitized cells to platinum and induced upregulation of cyclin D1 and c-Myc, suggesting that TMEM88 inhibited the Wnt signaling pathway.
In approximately 11% of high-grade serous ovarian cancer, BRCA1 promoter methylation is an important somatic driver. Using whole-genome sequencing of tumor and germline DNA samples from these patients, Patch et al. observed several molecular events associated with acquired resistance to carboplatin-combination treatment. They identified a patient who displayed extensive promoter methylation and low expression of BRCA1. During the relapse, the patient lost BRCA1 methylation and the gene was expressed at comparable levels to homologous-recombination-intact tumors. Comparison of the global methylation patterns of primary and recurrence samples suggested a specific rather than a generalized altered methylation status at relapse in this patient.
A phase 1 trial of low-dose decitabine combined with carboplatin in ten patients with recurrent, platinum-resistant ovarian cancer was performed by Fang et al. The most common toxicities were nausea, allergic reactions, neutropenia, fatigue, anorexia, vomiting and abdominal pain. LINE-1 hypomethylation in peripheral blood mononuclear cells (PBMCs) and hypermethylation of HOXA11 and BRCA1 in plasma were detected. One complete response was observed, and three additional patients had stable disease for about six months. Furthermore, a phase 1b-2a clinical trial of a sequential combination of azacitidine and carboplatin was initiated in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer by Fu et al. Among 29 evaluable patients, this treatment produced one complete response, three partial responses and ten cases of stable disease. The predominant toxicities were fatigue and myelosuppression. Correlative studies indicated that DNA methylation of the human leukocyte antigen death receptor 4 (DR4) in peripheral blood leukocytes was decreased during treatment in three of four objective responders, but in only five of 13 non-responders. In a phase 2 clinical trial, Matei et al. tested the clinical and biological activity of decitabine administered before carboplatin in platinum-resistant ovarian cancer patients. Low-dose decitabine altered DNA methylation along with the Wnt signaling and apoptosis pathways, restored the sensitivity to carboplatin in patients with heavily pretreated ovarian cancer and resulted in a high response rate and prolonged progression-free survival (PFS). Demethylation of the DNA mismatch repair gene MLH1, the tumor suppressor genes RASSF1A, HOXA10 and HOXA11 in tumors positively correlated with PFS.
Using an ovarian cancer cell line with acquired resistance to carboplatin and genome-wide microarray profiling, Coley et al. identified the CDK inhibitor p57 (Kip2) to be downregulated in carboplatin resistance. Methylation sites in the p57 promoter and even, a preferential sensitivity to seliciclib, a CDK inhibitor, were detected in the cell line. Silencing of p57 decreased the apoptotic response to the effects of platinum, but unexpectedly produced sensitization to seliciclib. High levels of p57 mRNA in tumor biopsies correlated with complete responses to chemotherapy and improved outcome.
The serine proteases urokinase plasminogen activator and tissue-type plasminogen activator together with their major physiological inhibitor, plasminogen activator inhibitor-1 [PAI-1; serine protease inhibitor clade E member 1 (SERPINE1)] have been identified as prognostic factors for disease progression and relapse in different cancer types since they play important roles in cell adhesion, migration and invasion. Recently, Pan et al. revealed that that SERPINE1 may be a promising therapeutic target for chemo-resistance of ovarian cancer cells. Microarray screening showed that carboplatin treatment caused hypomethylation of the promoter of SERPINE1, and consequently, significantly increased the expression of SERPINE1, resulting in induction of the EMT process with decreased expression of E-cadherin and increased expression of Vimentin, Snail and Twist.
As reported by Syed et al., DNA methylation of the Polo-like kinase Plk2 in tumor tissues and serum samples was associated with a higher risk of relapse in patients treated postoperatively with carboplatin and paclitaxel. They found that platinum resistance can be conferred by the downregulation of Plk2 transcripts via promotor methylation in ovarian cancer cells selected for paclitaxel and carboplatin resistance, primary tumors and patient sera. In the drug-resistant cells, Plk2 promoter methylation varied with the degree of drug resistance and transcriptional silencing of the promoter. Knockdown of Plk2 abrogated G2-M cell-cycle blockade by paclitaxel, conferring resistance to both paclitaxel and platinum. Contrary, ectopic expression of Plk2 restored sensitivity to G2-M cell cycle blockade and cytotoxicity triggered by paclitaxel.
Furthermore, Iramaneerat et al. demonstrated that the expression levels of human endogenous retrovirus (HERV) K and E were increased in tissues from patients with ovarian clear cell carcinoma (OCCC). Methylation levels of HERV were associated with treatment response and prognosis of OCCC. DNA methylation levels of HERV-K, HERV-E and LINE-1 were decreased in tissues from patients with advanced stage cancer. In particular, HERV-K was significantly less methylated in the platinum-resistant cohort. Hypomethylation of HERV-K correlated with a shorter overall and progression-free survival.
Apart from genetic events, epigenetic modification of the SFRP family has been shown to be important in regulating the Wnt signaling pathway. Su et al. demonstrated that restoration of SFRP5 expression attenuated Wnt signaling in ovarian cancer cells. Cancer cell growth, invasion of cells and tumorigenicity were inhibited in mice independently of the canonical pathway. Epigenetic silencing of SFRP5 led to oncogenic activation of the Wnt pathway and contributed to ovarian cancer progression and carboplatin resistance through the transcription factor Twist-mediated EMT and AKT2 signaling.
Finally, Glasspool et al. also tested the hypothesis whether a DNA hypomethylating agent can reverse resistance to carboplatin in women with relapsed ovarian cancer. Surprisingly, and in contrast to SGI-110, the administration of decitabine appeared to reduce rather than increase the efficacy of carboplatin in partially platinum-sensitive ovarian cancer patients. These findings provoked the authors to suggest that other demethylating agents should be considered in future combination studies.
To date, there are some studies that have compared the resistance to both, cis- and carboplatin. Using a comprehensive DNA methylation microarray platform, Nogales et al. investigated the relationship of resistance to both platinum compounds with the DNA methylation of the putative DNA/RNA helicase Schlafen-11 (SLFN11). They identified hypermethylation of promoter CpG sites associated with the silencing of this gene that correlated with increased resistance to cis- and carboplatin. Notably, their clinical findings showed that those ovarian cancer patients harboring epigenetic inactivation of SLFN11 had a poor response to both drugs.
In the biosynthesis of arginine, argininosuccinate synthetase (ASS1) is the rate-limiting enzyme. Down-regulation of its expression was associated with the development of platinum resistance in ovarian cancer. Nicholson et al. showed that ASS1 expression correlated with the ability of ovarian cancer cells to grow in media supplemented with cisplatin, carboplatin or taxol or in arginine-depleted media. Aberrant methylation of the ASS1 promoter correlated with transcriptional silencing in ovarian cancer cell lines leading to selective resistance to platinum-based drugs and conferred arginine auxotrophy and sensitivity to arginine deprivation. In ovarian cancer patients at diagnosis, ASS1 methylation was associated with significantly reduced overall survival and relapse-free survival. In patients who relapsed, ASS1 methylation was significantly more frequent compared to patients who did not relapse, suggesting that hypermethylated ASS1 contributes to treatment failure in ovarian cancer.
Metalloestrogens are metals that activate the estrogen receptor in the absence of estradiol. They encompass two subclasses: metal/metalloid anions and bivalent cationic metals. Arsenite and selenite belong to the subclass of metal/metalloid anions. Aebi et al. demonstrated that selection of cells for resistance to platinum resulted in resistance to arsenite and selenite. Since mammalian cells detoxify arsenite and selenite by S-adenosylmethionine dependent methylation, they examined whether the latter is involved in the cellular metabolism of cisplatin. Treatment of ovarian cancer cells and their cisplatin-resistant subline with the S-adenosylhomocysteine hydrolase inhibitor adenosine-dialdehyde, an indirect inhibitor of transmethylation, led to a significant increase in the cellular content of S-adenosylhomocysteine without changing S-adenosylmethionine. Adenosine dialdehyde synergistically enhanced the cytotoxicity of both, cisplatin and carboplatin. These findings indicate that inhibition of S-adenosylmethionine dependent transmethylation enhanced the toxicity of cisplatin and carboplatin in ovarian cancer cells in vitro without directly affecting the metabolism of either platinum drug.
Epigenetic modifications of histones include methylation, acetylation, phosphorylation, sumoylation, glycosylation, ubiquitination, carbonylation and ADP-ribosylation of individual histone components. Such histone modifications have a direct effect upon DNA through nucleohistone repositioning. Histone changes are heritable and can result in modification of gene expression. Furthermore, the epigenetic modifications of histones lead to the deregulation of miRNAs in tumor cells. The effect of epigenetic changes in ovarian cancer is well-reviewed by Yang et al.
The combination of DNA methylation inhibitors and HDAC inhibitors synergistically activates gene expression[90,91]. Thus, not only DNA methylation but also histone deacetylation has a central role in the transcriptional repression of tumor suppressor genes and genes involved in sensitivity to chemotherapy.
There are a few articles on the relationship of histone modifications to platinum resistance. In this regard, Cacan et al. identified HDAC and DNMT1 to exhibit an aberrant association with the regulator of G protein signaling 10 (RGS10) in chemoresistant ovarian cancer cells. Knockdown of HDAC1 or DNMT1 expression and pharmacological inhibition of DNMT or HDAC enzymatic activity significantly increased RGS10 expression and cisplatin-mediated cell death. Moreover, DNMT1 knockdown decreased HDAC1 binding to the RGS10 promoter in chemo-resistant cells, suggesting HDAC1 recruitment to RGS10 promoters requires DNMT1 activity.
In both in vitro (cisplatin-resistant ovarian cancer cells) and in vivo (xenografts), Steele et al. observed that the combination of decitabine and a clinically relevant inhibitor of HDAC activity (belinostat) increased the expression of epigenetically silenced MLH1 gene and MAGE-A1 antigen when compared with decitabine alone. The treatment that influenced the histone structure improved the efficacy of chemotherapy in tumors that had acquired drug resistance due to DNA methylation and gene silencing. Liu et al. also performed in vitro and in vivo studies. In cisplatin-resistant ovarian cancer cells, they showed that HDAC1 knockdown suppressed cell proliferation and increased apoptosis. The increase in chemo-sensitivity was caused by downregulating the oncogene c-Myc and upregulating miR-34a. Cisplatin treatment activated HDAC1 and c-Myc and inactivated miR-34a. Inhibition of HDAC1 reduced c-Myc expression, increased miR-34a expression and sensitized ovarian cancer cells to cisplatin-induced apoptosis. In vivo studies confirmed these findings. They showed that targeting HDAC1 sensitized murine xenograft models to cisplatin treatment. Cacan demonstrated that expression of the death receptor FAS is suppressed in cisplatin resistant ovarian cells compared to parental cells. Surprisingly, no difference in DNA methylation was observed at FAS promoters between both cell lines. However, there were a decrease in acetylated histone H3 and a corresponding increase in HDAC1 associated with FAS promoter in resistant cells. Knockdown of HDAC1 and pharmacological inhibition of HDAC enzymatic activity significantly increased FAS expression in resistant cells, suggesting that particularly histone modifications may contribute to the loss of FAS expression in cisplatin resistant ovarian cancer cells, and that enhancement of FAS expression may increase tumor cell sensitivity to immune cells.
Histone modifications in chemo-resistant cells were evaluated in relationship to oncolytic adenovirus efficacy by Hulin-Curtis et al.. In contrast to cisplatin-sensitive ovarian cells displaying an efficient shortening of cell viability by adenovirus in the presence of cisplatin, cisplatin-resistant cells diminished this reduction of cell viability mediated by adenovirus with increasing doses of cisplatin. HDAC2, and to a lesser extent HDAC1, were up-regulated in cisplatin-resistant but not in cisplatin-sensitive cells. Administration of cisplatin-resistant cells with trichostatin A (TSA), a HDAC inhibitor significantly enhanced adenovirus mediated reduction of cell viability in the presence of cisplatin. Cells treated with TSA alone did not display this effect, indicating an adenovirus dependent mechanism.
In a phase I trial, Falchook et al. demonstrated that sequential treatment with a combination of the nucleoside analogue azacytidine, the HDAC valproic acid and carboplatin decreased DR4 methylation, but there was no relationship with either tumor response or number of therapy cycles received. A modest evidence of antitumor activity could only be observed in patients with heavily treated advanced malignancies.
Besides DNA methylation, the dysregulation of microRNAs (miRNAs) may also be responsible for the induction of acquired platinum resistance in ovarian cancer. MiRNAs are, together with long non-coding RNAs (lncRNAs) and small RNAs, members of the non-coding RNAs (ncRNAs). Whilst lncRNAs have been confirmed to be epigenetically modified, it is only recently that miRNA epigenetic modifications have been identified and related to cancer. MiRNAs are small ncRNAs that bind to 3’-untranslated regions of target mRNA in a sequence-specific fashion and either inhibit the translation of their target mRNA or degrade it. MiRNAs are involved in both normal and cancer cellular processes linked to cell division, growth, differentiation and ageing. Their behavior is complex in that they are present in both, the nucleus and cytoplasm, and their nuclear presence permits them to control gene expression[101,102]. However, subgroups of miRNAs, e.g., deregulated epi-miRNAs present in different cancer types target specific epigenetic regulators, such as DNMT and histone deacetylase[103,104].
A number of clinically regulated miRNAs have been identified in ovarian cancer. These include upregulated miRNAs, miR-15a/16 miR-20a, miR-23a/b, miR-30a/b/c, miR-92, miR-93, miR-106a, miR-146b, miR-182, miR-200, miR-203, miR-205, miR-223 and downregulated Let-7a/b/d/f, miR-22, miR-31, miR-34a/b/c, miR-125b, miR-127-3p, miR-152, miR-155, miR-181a-3p, miR-382.
A wealth of publications deals with the role of miRNAs in platinum resistance [Table 3]. For example, Vera et al. identified four miRNAs (miR-7, miR-132, miR-335 and miR-148a) the deregulation of which appears to be a common event in the development of resistance to cisplatin in ovarian cancer. In particular, the specific DNA methylation of miR-7 in cisplatin-resistant cell lines was associated with a poor prognosis in ovarian cancer patients. The direct regulation of MAFG by miR-7 seems to cause this resistance.
MiRNAs in cis- and carboplatin resistance
|miR-21||Up-||NAV3, PTEN, c-IAP2, PDCD4||[112,147-149]|
|MAPK signaling pathway
BRCA1, RB1, CDK1, ABL1, CCNA1
MET, SHC1, EGFR, INPPL1
MET, SHC1, EGFR, INPPL1
|miR-93||Down-||DNA polymerase η|||
|miR-130a||Down-/up-||MDR1, PTEN, XIAP||[159-162]|
|miR-130b||Down-||CSF-1, MDR1, GST-π||[117,163]|
|miR-142-5p||Down-||XIAP, BIRC3, BCL2, BCL2L2, MCL1|||
|miR-186||Down-||MDR1 (ABCB1), GST-π, Twist1||[169,170]|
|miR-199a||Down-||DDR1, ITGB8, mTOR||[125,171,172]|
|miR-224-5p||Up-||protein kinase C|||
|miR-483-3p||Up-||protein kinase Cd|||
|miR-634||Down-||CCND1, GRB2, ERK2, RSK2|||
|miR-484||DOwn-||VEGF B, VEGF receptor 2|||
|Cis- and carboplatin resistance|
The human let-7 family comprises 13 members located on nine different chromosomes. The majority of the members is involved in the modulation of drug sensitivity in different cancer types. In epithelial ovarian cancer, the laboratory of Wang demonstrated that deregulation of let-7e promoted the development of resistance to cisplatin. In situ hybridization revealed significantly lower expression levels of let-7e in chemo-resistant than chemo-sensitive ovarian cancer tissues. Transfection with let-7e sensitized ovarian cancer cells to cisplatin, down-regulated BRCA1 and Rad51 expression and repressed the repair of cisplatin-induced DNA double strand break. Low let-7e and high Rad51 levels were significantly associated with poor overall and progression-free survival. Multivariate regression and receiver operating characteristic analyses showed that let-7e was an independent predictor for chemotherapy response and highly predictive of resistance to cisplatin, suggesting that re-expression of let-7e may be an effective strategy for overcoming chemo-resistance. Zhao et al. revealed that primary cancer cells from drug sensitive patients are more tumorigenic than those from drug resistant women. In 26 drug-sensitive patients, the expression levels of miR-9, miR-145 and miR-429 were higher than in 20 drug-resistant cases. Conversely, higher miR-26a expression was observed in resistant patients. Inhibition of miR-9 resulted in decreased clonal cell formation and sensitivity to cisplatin, while knockdown of the other three miRNAs did not influence drug sensitivity. Sun et al. analyzed the effects of miR-9 on cisplatin and PARP [Poly(ADP ribose) polymerase] inhibitor sensitivity in ovarian cancer cells and xenograft mice. The impact of miR-9 on prognosis was assessed in a cohort of 113 ovarian cancer patients. In ovarian cancer cells, miR-9 bound directly to the 3’-UTR of BRCA1, downregulated BRCA1 expression and impeded DNA damage repair. Treatment with miR-9 sensitized BRCA1-proficient xenograft tumors to cisplatin. Patients with higher levels of miR-9 had better chemotherapy responses, platinum sensitivity and longer progression-free survival.
Using microarrays, Pink et al. identified miR-21-3p, the passenger strand of the known oncogenic miR-21, to direct increased resistance to cisplatin in a range of ovarian cell lines, whereas miR-21-5p had an opposite effect and increased cisplatin sensitivity. The induction of resistance to cisplatin by miR-21-3p may be caused by the binding to its mRNA target of the neuron navigator NAV3. NAV3 is involved in axon guidance during development and its knockdown increased resistance to cisplatin.
Jin et al. showed that inhibition of miR-23a expression could significantly increase the sensitivity to cisplatin in ovarian cancer cells. The cells were arrested in G0/G1 phase along with an increased apoptosis rate. In addition, the expression levels of P-glycoprotein involved in multi-drug resistance (MDR) decreased with increasing cisplatin concentrations.
Using microarrays and RNA-sequencing, Samuel et al. assessed the role of miR-31 in the development of chemo-resistance to cisplatin. They found increased levels of miR-31 and reduced levels of potassium channel calcium activated large conductance subfamily M alpha, member 1 (KCNMA1), a subunit of calcium-regulated big potassium (BK) channels in resistant ovarian cells. Overexpression of miR-31, knockdown of KCNMA1 or inhibition of BK channels increased resistance to cisplatin, suggesting that this resistance was mediated by the repression of KCNMA1 through miR-31.
Recently, Lv et al. showed that the overexpression of HDAC1 decreased cisplatin sensitivity, promoted proliferation and blocked the suppressive effects of miR-34a on cell proliferation in ovarian cancer cells. Accordingly, miR-34a directly bound to HDAC1, and downregulated its expression, which subsequently decreased the resistance to cisplatin and suppressed proliferation in ovarian cancer cells.
In both epithelial ovarian cancer cell lines and ovarian carcinomas, Li et al. analyzed the expression of miR-128 and its targeted genes, the polycomb ring finger oncogene Bmi-1 and the ATP-binding cassette subfamily C member 5 (ABCC5). MiR-128 expression was significantly reduced in the cisplatin-resistant ovarian cancer cell line compared with its parental SKOV3 cells, and decreased upon treatment with cisplatin in a concentration-dependent manner. Overexpression of miR-128 re-sensitized the cells to cisplatin and reduced the expression of cisplatin-resistant-related proteins ABCC5 and Bmi-1. Administration of a combination of cisplatin and miR-128 inhibited the growth of cisplatin resistant xenograft tumors more effectively than cisplatin alone.
Investigating the role of miR-130b in the development of multidrug-resistance, Yang et al. detected that down-regulation of miR-130b in ovarian cancer correlated with FIGO III-IV clinical stages, poor histological differentiation and its hypermethylation. Demethylation by the treatment with 5-aza-CdR re-activated miR-130b expression in drug resistant ovarian cancer cell lines along with an increase in sensitivity to cisplatin and taxol. Thus, downregulation of miR-130b promotes the development of multidrug resistant ovarian cancer partially by binding of miR-130b to its target mRNA of the colony-stimulating factor 1 (CSF-1).
As reported by Zhao et al., miR-136 expression was significantly reduced in 34 primary platinum-resistant patients and an ovarian cancer cell line. Overexpression of miR-136 decreased the chemo-resistance to cisplatin in ovarian cancer cells through inhibition of cell survival and promoting an apoptotic response to cisplatin. The percentage of DNA in comet tails, tail length, tail moment and olive tail moment exposed the relevance of miR-136 in the repair of cisplatin-induced DNA damage.
MiRNA-139 has been characterized as a tumor suppressor with anti-oncogenic and anti-metastatic activity and consequently, is downregulated in different cancer types[119-121]. Jiang et al. revealed that the expression of miR-139-5p was decreased in cisplatin-resistant ovarian cancer cell lines. Re-expression of miR-139-5p increased the sensitivity of these cells to cisplatin treatment, inhibited the expression of the activator protein-1 transcription factor component c-Jun through binding to the 3´UTR of c-Jun mRNA, and decreased the expression of the BCL family member BCL-xL, promoting cisplatin-induced mitochondrial apoptosis.
Oxidative and electrophilic changes in cells are mainly coordinated by the KEAP1/NRF2 [Kelch-like erythroid-derived cap-n-collar homology- (ECH-) associated protein-1/nuclear factor (erythroid-derived 2)-like 2] axis. Electrophiles react with critical thiol groups of KEAP1 causing the loss of its ability to inhibit NRF2. The KEAP1/NRF2 signaling pathway also down-regulates NF-κB transcriptional activity and attenuates cytokine-mediated induction of pro-inflammatory genes. van Jaarsveld et al. demonstrated that miR-141 directly targets KEAP1, and that downregulation of KEAP1 induced cisplatin resistance. Conversely, overexpression of KEAP1 significantly enhanced cisplatin sensitivity. The NF-κB pathway, which is regulated by KEAP1, was activated upon miR-141 overexpression, while inhibition of this pathway partially reversed miR-141-mediated cisplatin resistance. Furthermore, van Jaarsveld et al. quantified the expression levels of miR-141 in 108 serous and 24 non-serous primary ovarian tumors. They found that its levels were elevated in non-serous ovarian tumors that did not respond well to therapy.
A negative correlation between the collagen receptor tyrosine kinase Discoidin Domain Receptor 1 (DDR1) and miR-199a-3p was detected by Deng et al. in ovarian cancer tissues. Cell culture experiments confirmed that miR-199a-3p decreased the expression of DDR1 via binding to DDR1 mRNA. In ovarian cancer cells, the miR-199a promoter was hypermethylated, but not in normal cells. Knockdown of DNMT3A increased miR-199a-3p expression and attenuated the expression of DDR1 in ovarian cancer cells, while overexpression of miR-199a-3p impaired the migratory, invasive and tumorigenic capabilities of ovarian cancer cells as well as enhanced cisplatin resistance through inhibiting DDR1 expression.
Using miRNA microarray analyses, Zhao et al. demonstrated that upregulation of miR-224-5p was associated with platinum-based chemo-resistance in ovarian cancer patients. They identified the protein kinase Cδ gene as one of the targets of miR-224-5p in mediating resistance to cisplatin in ovarian cancer patients. These findings indicate that miR-224-5p and protein kinase Cδ can serve as predictors and prognostic biomarkers for ovarian papillary serous cancer patient response to overall disease-specific survival.
The Notch receptor family plays an important role in cell differentiation, organ development and tumorigenesis, tumor progression, invasion and metastasis. The activation of the Notch signaling pathway can both accelerate and restrain tumorigenesis, depending on the cell environment. Zhou et al. demonstrated that ectopically expressed miR-449a increased cisplatin sensitivity in cisplatin-resistant ovarian cell lines through targeting Notch1 transcripts, inhibited cell proliferation and promoted apoptosis. These findings were confirmed with in vitro experiments. When BALB/c nude mice were injected intraperitoneally with cisplatin-resistant ovarian cancer cells transfected with miR-449a, they exhibited enhanced cisplatin sensitivity in vivo.
Based on the interplay between miR-483-3p and protein kinase Cδ, Arrighetti et al. explained the mechanism of resistance to cisplatin. They observed that miR-483-3p usually involved in apoptosis and cell proliferation was up-regulated in cisplatin resistant ovarian cancer cells. This up-regulation of miR-483-3p and possibly its binding to protein kinase Cδ mRNA interfered with the proliferation of resistant ovarian cancer cells, thus, protecting them from DNA damage induced by platinum compounds.
MiR-509-3p has been reported to sensitize ovarian cancer cells to cisplatin treatment by targeting multiple anti-apoptosis genes including BCL2[129,130]. Niu et al. compared the expression profiles of miRNAs between three pairs of platinum-resistant and platinum-sensitive ovarian tissues and found that miR-509-3p was significantly down-regulated in cisplatin-resistant ovarian cancer tissues. Functional studies demonstrated that miR-509-3p inhibitor decreased cell response to cisplatin and promoted cell survival in ovarian cancer cells. In this process, miR-509-3p regulated the expression of Golgi phosphoprotein-3 (GOLPH3) and wntless Wnt ligand secretion mediator (WLS).
Previously, Zhang et al. detected that miR-520g contributes to tumor progression and cisplatin resistance by post-transcriptionally downregulating its target mRNA of death-associated protein kinase 2 (DAPK2). MiR-520g expression gradually increased across normal, benign, borderline and ovarian cancer tissues. High miR-520g levels promoted tumor progression and chemo-resistance to cisplatin, and reduced survival in ovarian cancer patients. DAPK2 overexpression or miR-520g knockdown reduced ovarian cancer cell proliferation, invasion, wound healing and chemo-resistance.
Ovarian cancer stem cells are involved in tumor growth, metastasis and recurrence. The main characteristics of this subpopulation of cancer cells are their uncontrolled proliferation, high invasiveness and resistance to the current platinum-based therapies. Using a quantitative PCR array, Wei et al. demonstrated that miR-551b was upregulated in ovarian cancer stem cells and that its levels correlated with the pathological grades. In vitro experiments indicated that miR-551b inhibited the transcription factor forkhead box O3 and RING finger, B-box and coiled-coil domain protein TRIM31 (tripartite motif), promoted proliferation, invasion and chemo-resistance of ovarian cancer cells and cancer stem cells. Accordingly, in mouse xenograft models, the inhibition of miR-551b significantly increased the susceptibility of ovarian cancer cells to cisplatin and prolonged the survival of the host mice.
Excision repair crossing-complementing group 2 (ERCC2), also called xeroderma pigmentosum complementary group D (XPD), plays a crucial role in the nucleotide excision repair pathway. In concert with XPA, ERCCR2 verifies the presence of a relevant base lesion by scanning a DNA strand in the 5'-3' direction, so ensuring the accurate removal of the lesion from the genome. In this regard, Zhao et al. examined the function of miR-770-5p which targets ERCCR2 in cisplatin chemotherapy resistance in ovarian cancer patients. MiR-770-5p expression was reduced in these patients. Overexpression of miR-770-5p reduced survival in chemo-resistant cell lines after cisplatin treatment by downregulating ERCC2. A comet assay confirmed that the restoration of cisplatin chemo-sensitivity was due to the inhibition of DNA repair.
The insulin-like growth factor-1 receptor (IGF-1R) is expressed on most transformed cells, where it has anti-apoptotic, cell-survival and transforming activities. Its activation is a hallmark for tumor initiation and progression. Zhang et al. investigated the effect of miR-1294 on platinum-resistant ovarian cancer and documented that miR-1294 dysregulation manipulated ovarian cancer cisplatin resistance through regulating IGF1R. Knockdown of IGF1R decreased cell proliferation, migration, invasion and EMT of cisplatin-resistant cells. Overexpression of miR-1294 inhibited cisplatin resistance, suggesting that epigenetic regulation of IGF1R by miR-1294 was essential for cisplatin resistance.
Our previous data indicated the relevance of dysregulated plasma miR-146a in different breast cancer subtypes, suggesting its potential role in breast cancer biology and tumor progression. Wilczyński et al. compared miR-146a expression levels in primary tumors and omental metastases of 48 patients who had undergone surgery of advanced ovarian serous cancer. The miR-146a levels in primary tumors were elevated compared with normal ovary tissues and metastases. There was a negative correlation between miR-146a expression in primary tumors and serum amounts of cancer antigen 125 (CA125). Decreased miR-146a expression was associated with a shorter overall and progression-free survival, most notably with carboplatin resistance of metastases.
Using real-time qPCR miRNA OpenArrays, Benson et al. measured miRNA concentrations in plasma samples from 14 patients with platinum-resistant, recurrent ovarian cancer enrolled in a phase II clinical trial that were treated with a low dose of the hypomethylating agent decitabine followed by carboplatin. Ten miRNAs (miR-193a-5p, miR-375, miR-339-3p, miR-340-5p, miR-532-3p, miR-133a-3p, miR-25-3p, miR-10a-5p, miR-616-5p and miR-148b-5p) displayed multi-fold changes in concentrations in recurrent platinum resistant ovarian cancer patients that were associated with a response to decitabine followed by carboplatin chemotherapy. In addition, circulating miR-148b-5p concentrations were associated with progression-free survival and may represent a novel biomarker for therapeutic response to this chemotherapy regimen in patients with recurrent, drug-resistant ovarian cancer.
MiRNA can be released by apoptotic and necrotic cells into the blood circulation, but they can also be actively secreted in extracellular vesicles (EVs). EVs are thought to play an important role in cell-to-cell communication. In this regard, Kuhlmann et al. designed an integrated NGS-based workflow for analyzing the signature of EV-associated miRNAs in the plasma of platinum-resistant ovarian cancer patients. They found a panel of EV-associated miRNAs, such as miR-181a, miR-1908, miR-21, miR-486 and miR-223, which were differentially abundant in the plasma of platinum-resistant patients.
BRCA1 and BRCA2 play an important role in the homologous recombination DNA repair system. Cells harboring mutations of BRCA1/BRCA2 are especially sensitive to platinum. Furthermore, the Ku heterodimer consisting of two subunits (Ku70 and Ku80) plays a central role as an initial DNA end binding factor in the classical non-homologous end joining pathway. Choi et al. detected a resistance mechanism by which miR-622 induced cis- and carboplatin resistance in BRCA1 mutant high-grade serous ovarian carcinomas by targeting the Ku complex and restoring homologous recombination mediated double strand break repair. MiR-622 inversely correlated with Ku expression during the cell cycle, suppressed non-homologous end-joining, but facilitated homologous recombination mediated double strand break repair in the S phase. Notably, a high expression of miR-622 in BRCA1-deficient high-grade serous ovarian carcinomas correlated with worse outcome after platinum chemotherapy.
Despite recent advances in treatment regimens, ovarian cancer remains one of the most deadly diseases because of its development of drug resistance. Due to the high number of relapsed ovarian cancer patients, new therapy options for platinum resistant disease are needed. The cytotoxicity of platinum is based on the formation of DNA adducts, including DNA-protein cross-links, DNA monoadducts and interstrand DNA cross-links, activating DNA damage and consequently, the cell death pathway. However, the events leading to platinum resistance are not well understood. Besides genetic alterations, changes in epigenetic regulation may contribute to this resistance. In particular, epigenetically silenced tumor suppressor genes involved in apoptosis, DNA repair and the cell cycle may be the main reasons for drug resistance. As shown by previous studies and described above, among other factors, BRCA1, BRCA2, MLH1, p53 and p21 contribute to platinum resistance via DNA damage and repair, while p21, RASSF1, Bax and p53 contribute via apoptosis. The most relevant signaling pathways and processes participating in platinum resistance include Wnt, PI3K/Akt, Notch, NF-κB and EMT. As specified above, epigenetic therapies appear to be promising therapy strategies. Combined administration of DNMT and HDAC inhibitors may re-express silenced tumor suppressor genes. Moreover, changes in the methylation profiles of ovarian cancer have led to the testing of new combination treatment regimes. Therapeutics to inhibit DNMT, including azacitidine and decitabine, were successfully developed and approved for treatment. In 2010, Fang et al. were the first to assess decitabine at repeated low doses to reduce DNA methylation and re-instate cisplatin sensitivity in a Phase 1 clinical trial of HGSOC patients. Other therapeutic agents that target methylation include SGI-110 as a nucleoside analogue and valproic acid, and seem to be beneficial in the treatment of diverse cancer types.
Further epigenetic targets could be miRNAs that are also involved in tumor suppressor silencing. Accordingly, miRNAs are attractive candidates for developing a new class of drugs that specifically target miRNA pathways. For example, promising targets to date are miR-622 that targets the Ku pathway and miR-484 that targets both VEGFB and VEGFR2 pathways as well as tumor vasculature. As reviewed above, many other miRNAs have also been associated with resistance to cis- and carboplatin in ovarian cancer. Therefore, determining which miRNAs are the best for miRNA targeted therapy development will be a challenge. In this regard, several mechanisms to target miRNAs are currently in development for cancer treatment. Down-regulation of target oncogenes by re-expression of tumor suppressor miRNAs, or re-expression of tumor suppressor genes by silencing of oncogenic miRNAs is anticipated to sensitize tumor to platinum treatment. Restoring and blocking miRNA function may be performed by replacement of tumor suppressor miRNAs with either synthetic or viral vectors encoded for miRNA mimics, or by antisense-mediated inhibition of oncogenic miRNAs, respectively. The above studies provide promising results to re-sensitize both ovarian cancer cell lines and animal models to platinum therapy, so laying the basis for effective epigenetic drugs in combination with platinum-based agents. In future, cis- or carboplatin therapies combined with epigenetic drugs may shed light on the potential of personalized treatment modalities to overcome resistance in women with recurrent ovarian cancer.
Both authors contribute equally to the manuscript.Availability of data and materials
Not applicable.Financial support and sponsorship
None.Conflicts of interest
Both authors declare that there are no conflicts of interest.Ethical approval and consent to participate
Not applicable.Consent for publication
© The Author(s) 2019.
1. Noble D. Conrad Waddington and the origin of epigenetics. J Exp Biol 2015;218:816-8.DOIPubMed
2. Waddington CH. The Epigenotype Endeavour 1942. pp. 18-20.
3. Waddington CH. The genetic basis of the 'assimilated bithorax' stock. J Genet 2006;85:101-5.PubMed
4. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59.DOIPubMed
5. Yang Q, Yang Y, Zhou N, Tang K, Lau WB, et al. Epigenetics in ovarian cancer: premise, properties, and perspectives. Mol Cancer 2018;17:109.DOIPubMedPMC
6. Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature 1965;205:698-9.PubMed
7. Rosenberg B, VanCamp L. The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res 1970;30:1799-802.PubMed
8. Wilting RH, Dannenberg JH. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat 2012;15:21-38.DOIPubMed
9. Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med 2012;367:647-57.DOIPubMed
10. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, et al. Molecular biology of the cell. 5th ed. New York: Garland Science Publishing, Taylor & Francis Group; 2008.
11. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-16.DOIPubMed
12. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000;92:564-9.DOIPubMed
13. Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999;18:1957-65.DOIPubMed
14. Gozzi G, Chelbi ST, Manni P, Alberti L, Fonda S, et al. Promoter methylation and downregulated expression of the TBX15 gene in ovarian carcinoma. Oncol Lett 2016;12:2811-9.DOIPubMedPMC
15. Li Q, Xue X, Li W, Wang Q, Han L, et al. Heterogeneous DNA methylation status in same-cell subpopulations of ovarian cancer tissues. Tumour Biol 2017;39:1010428317701650.DOIPubMed
16. Losi L, Fonda S, Saponaro S, Chelbi ST, Lancellotti C, et al. Distinct DNA methylation profiles in ovarian tumors: opportunities for novel biomarkers. Int J Mol Sci 2018;19.DOIPubMedPMC
17. Choi JD, Lee JS. Interplay between epigenetics and genetics in cancer. Genomics Inform 2013;11:164-73.DOIPubMedPMC
18. Yang SD, Ahn SH, Kim JI. 3-Oxoacid CoA transferase 1 as a therapeutic target gene for cisplatin-resistant ovarian cancer. Oncol Lett 2018;15:2611-8.DOIPubMedPMC
19. Lund RJ, Huhtinen K, Salmi J, Rantala J, Nguyen EV, et al. DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer. Sci Rep 2017;7:1469.DOIPubMedPMC
20. Han X, Zhou Y, You Y, Lu J, Wang L, et al. TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer. Cell Biol Int 2017;41:405-14.DOIPubMed
21. Fang F, Munck J, Tang J, Taverna P, Wang Y, et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin Cancer Res 2014;20:6504-16.DOIPubMedPMC
22. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 2012;31:4567-76.DOIPubMed
23. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999;18:2335-41.DOIPubMed
24. Matei D, Fang F, Shen C, Schilder J, Arnold A, et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012;72:2197-205.DOIPubMedPMC
25. Ha YN, Sung HY, Yang SD, Chae YJ, Ju W, et al. Epigenetic modification of alpha-N-acetylgalactosaminidase enhances cisplatin resistance in ovarian cancer. Korean J Physiol Pharmacol 2018;22:43-51.DOIPubMedPMC
26. Jin C, Yu W, Lou X, Zhou F, Han X, et al. UCHL1 is a putative tumor suppressor in ovarian cancer cells and contributes to cisplatin resistance. J Cancer 2013;4:662-70.DOIPubMedPMC
27. Yu W, Jin C, Lou X, Han X, Li L, et al. Global analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell. PLoS One 2011;6:e29450.DOIPubMedPMC
28. Olopade OI, Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 2003;3:417-20.DOIPubMed
29. D'Andrea AD. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2003;2:290-2.DOIPubMed
30. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568-74.DOIPubMed
31. Bonito NA, Borley J, Wilhelm-Benartzi CS, Ghaem-Maghami S, Brown R. Epigenetic regulation of the homeobox gene MSX1 associates with platinum-resistant disease in high-grade serous epithelial ovarian cancer. Clin Cancer Res 2016;22:3097-104.DOIPubMedPMC
32. Cui L, Liang B, Yang Y, Zhu M, Kwong J, et al. Inhibition of coiled coil domain containing protein 69 enhances platinum-induced apoptosis in ovarian cancer cells. Oncotarget 2017;8:101634-48.DOIPubMedPMC
33. de Leon M, Cardenas H, Vieth E, Emerson R, Segar M, Liu Y, Nephew K, Matei D. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer. Gynecol Oncol 2016;142:539-47.DOIPubMedPMC
34. Lum E, Vigliotti M, Banerjee N, Cutter N, Wrzeszczynski KO, et al. Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis. Gynecol Oncol 2013;130:369-76.DOIPubMed
35. Fang F, Cardenas H, Huang H, Jiang G, Perkins SM, et al. Genomic and epigenomic signatures in ovarian cancer associated with resensitization to platinum drugs. Cancer Res 2018;78:631-44.DOIPubMedPMC
36. Coley HM, Safuwan NA, Chivers P, Papacharalbous E, Giannopoulos T, et al. The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer. Br J Cancer 2012;106:482-9.DOIPubMedPMC
37. Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, et al. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res 2011;71:3317-27.DOIPubMed
38. Iramaneerat K, Rattanatunyong P, Khemapech N, Triratanachat S, Mutirangura A. HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance. Int J Gynecol Cancer 2011;21:51-7.DOIPubMed
39. Su HY, Lai HC, Lin YW, Liu CY, Chen CK, et al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 2010;127:555-67.DOIPubMed
40. Nogales V, Reinhold WC, Varma S, Martinez-Cardus A, Moutinho C, et al. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget 2016;7:3084-97.DOIPubMedPMC
41. Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, et al. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer 2009;125:1454-63.DOIPubMed
42. Olkhov-Mitsel E, Bapat B. Strategies for discovery and validation of methylated and hydroxymethylated DNA biomarkers. Cancer Med 2012;1:237-60.DOIPubMedPMC
43. Kurdyukov S, Bullock M. DNA methylation analysis: choosing the right method. Biology (Basel) 2016;5:E3.DOIPubMedPMC
44. Guilleret I, Losi L, Chelbi ST, Fonda S, Bougel S, et al. DNA methylation profiling of esophageal adenocarcinoma using methylation ligation-dependent macroarray (MLM). Biochem Biophys Res Commun 2016;479:231-7.DOIPubMed
45. Kagohara LT, Stein-O'Brien GL, Kelley D, Flam E, Wick HC, et al. Epigenetic regulation of gene expression in cancer: techniques, resources and analysis. Brief Funct Genomics 2018;17:49-63.DOIPubMedPMC
46. Cock-Rada A, Weitzman JB. The methylation landscape of tumour metastasis. Biol Cell 2013;105:73-90.DOIPubMed
47. Deng J, Wang L, Chen H, Hao J, Ni J, et al. Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget 2016;7:55771-88.DOIPubMedPMC
48. Surana R, Sikka S, Cai W, Shin EM, Warrier SR, et al. Secreted frizzled related proteins: Implications in cancers. Biochim Biophys Acta 2014;1845:53-65.DOIPubMed
49. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008;8:187-98.DOIPubMed
50. Fazio C, Ricciardiello L. Inflammation and Notch signaling: a crosstalk with opposite effects on tumorigenesis. Cell Death Dis 2016;7:e2515.DOIPubMedPMC
51. Volarevic V, Djokovic B, Jankovic MG, Harrell CR, Fellabaum C, et al. Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci 2019;26:25.DOIPubMedPMC
52. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9-23.DOIPubMedPMC
53. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014;740:364-78.DOIPubMedPMC
54. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007;63:12-31.DOIPubMed
55. Holzer AK, Katano K, Klomp LW, Howell SB. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res 2004;10:6744-9.DOIPubMed
56. Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 2010;77:887-94.DOIPubMedPMC
57. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 1992;89:3070-4.DOIPubMedPMC
58. Jendzelovsky R, Jendzelovska Z, Hilovska L, Koval J, Mikes J, et al. Proadifen sensitizes resistant ovarian adenocarcinoma cells to cisplatin. Toxicol Lett 2016;243:56-66.DOIPubMed
59. Damia G, Broggini M. Platinum resistance in ovarian cancer: role of DNA repair. Cancers (Basel) 2019;11:E119.DOIPubMedPMC
60. Nie J, Liu L, Li X, Han W. Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors. Cancer Lett 2014;354:12-20.DOIPubMed
61. Derissen EJ, Beijnen JH, Schellens JH. Concise drug review: azacitidine and decitabine. Oncologist 2013;18:619-24.DOIPubMedPMC
62. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2009;2:34.DOIPubMedPMC
63. Singh V, Sharma P, Capalash N. DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer. Curr Cancer Drug Targets 2013;13:379-99.DOIPubMed
64. Samudio-Ruiz SL, Hudson LG. Increased DNA methyltransferase activity and DNA methylation following epidermal growth factor stimulation in ovarian cancer cells. Epigenetics 2012;7:216-24.DOIPubMedPMC
65. Granados ML, Hudson LG, Samudio-Ruiz SL. Contributions of the epidermal growth factor receptor to acquisition of platinum resistance in ovarian cancer cells. PLoS One 2015;10:e0136893.DOIPubMedPMC
66. Zhao Y, Li Q, Wu X, Chen P. Upregulation of p27Kip1 by demethylation sensitizes cisplatin-resistant human ovarian cancer SKOV3 cells. Mol Med Rep 2016;14:1659-66.DOIPubMed
67. Kritsch D, Hoffmann F, Steinbach D, Jansen L, Mary Photini S, et al. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer. Int J Cancer 2017;141:1600-14.DOIPubMed
68. Salome M, Campos J, Keeshan K. TRIB2 and the ubiquitin proteasome system in cancer. Biochem Soc Trans 2015;43:1089-94.DOIPubMed
69. Zhang S, Xie C. The role of OXCT1 in the pathogenesis of cancer as a rate-limiting enzyme of ketone body metabolism. Life Sci 2017;183:110-5.DOIPubMed
70. Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, et al. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res 2009;15:2448-55.DOIPubMedPMC
71. Lee PS, Teaberry VS, Bland AE, Huang Z, Whitaker RS, et al. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. Int J Cancer 2010;126:1378-89.DOIPubMed
72. Yamamoto N, Naraparaju VR, Moore M, Brent LH. Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1997;82:290-8.DOIPubMed
73. Fang Y, Shen X. Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications. Cancer Metastasis Rev 2017;36:669-82.DOIPubMed
74. Garcia MJ, Benitez J. The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets. Clin Transl Oncol 2008;10:78-84.DOIPubMed
75. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009;15:1126-32.DOIPubMedPMC
76. Karaca B, Atmaca H, Bozkurt E, Kisim A, Uzunoglu S, et al. Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells. Mol Biol Rep 2013;40:3925-33.DOIPubMed
77. Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002;94:61-7.DOIPubMed
78. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015;521:489-94.DOIPubMed
79. Fang F, Balch C, Schilder J, Breen T, Zhang S, et al. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 2010;116:4043-53.DOIPubMedPMC
80. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2011;117:1661-9.DOIPubMedPMC
81. Li S, Wei X, He J, Tian X, Yuan S, et al. Plasminogen activator inhibitor-1 in cancer research. Biomed Pharmacother 2018;105:83-94.DOIPubMed
82. Pan JX, Qu F, Wang FF, Xu J, Mu LS, et al. Aberrant SERPINE1 DNA methylation is involved in carboplatin induced epithelial-mesenchymal transition in epithelial ovarian cancer. Arch Gynecol Obstet 2017;296:1145-52.DOIPubMed
83. Glasspool RM, Brown R, Gore ME, Rustin GJ, McNeish IA, et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br J Cancer 2014;110:1923-9.DOIPubMedPMC
84. Morris SM, Jr. Enzymes of arginine metabolism. J Nutr 2004;134:2743S-7. discussion 2765S-7PubMed
85. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 2010;126:2762-72.DOIPubMed
86. Byrne C, Divekar SD, Storchan GB, Parodi DA, Martin MB. Metals and breast cancer. J Mammary Gland Biol Neoplasia 2013;18:63-73.DOIPubMedPMC
87. Aebi S, Christen R, Naredi P, Cenni B, Fink D, et al. Synergy between cisplatin and an inhibitor of S-adenosylmethionine dependent transmethylation in human ovarian adenocarcinoma cells. Int J Oncol 1997;11:869-74.DOIPubMed
88. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41-5.DOIPubMed
89. Maradeo ME, Cairns P. Translational application of epigenetic alterations: ovarian cancer as a model. FEBS Lett 2011;585:2112-20.DOIPubMedPMC
90. Nguyen HT, Tian G, Murph MM. Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise? Front Oncol 2014;4:71.DOIPubMedPMC
91. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006;4:339-49.DOIPubMed
92. Cacan E, Ali MW, Boyd NH, Hooks SB, Greer SF. Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance. PLoS One 2014;9:e87455.DOIPubMedPMC
93. Steele N, Finn P, Brown R, Plumb JA. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 2009;100:758-63.DOIPubMedPMC
94. Liu X, Yu Y, Zhang J, Lu C, Wang L, et al. HDAC1 silencing in ovarian cancer enhances the chemotherapy response. Cell Physiol Biochem 2018;48:1505-18.DOIPubMed
95. Cacan E. Histone Deacetylase-1-mediated Suppression of FAS in Chemoresistant Ovarian Cancer Cells. Anticancer Res 2016;36:2819-26.PubMed
96. Hulin-Curtis SL, Davies JA, Jones R, Hudson E, Hanna L, et al. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget 2018;9:26328-41.DOIPubMedPMC
97. Falchook GS, Fu S, Naing A, Hong DS, Hu W, et al. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs 2013;31:1192-200.DOIPubMedPMC
98. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell 2016;29:452-63.DOIPubMedPMC
99. Piletic K, Kunej T. MicroRNA epigenetic signatures in human disease. Arch Toxicol 2016;90:2405-19.DOIPubMed
100. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006;66:7390-4.DOIPubMed
101. Moreno-Moya JM, Vilella F, Simon C. MicroRNA: key gene expression regulators. Fertil Steril 2014;101:1516-23.DOIPubMed
102. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006;11:441-50.DOIPubMed
103. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007;104:15805-10.DOIPubMedPMC
104. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009;113:6411-8.DOIPubMedPMC
105. Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly KA, et al. Clinically relevant microRNAs in ovarian cancer. Mol Cancer Res 2015;13:393-401.DOIPubMedPMC
106. Vera O, Jimenez J, Pernia O, Rodriguez-Antolin C, Rodriguez C, et al. DNA methylation of miR-7 is a mechanism involved in platinum response through MAFG overexpression in cancer cells. Theranostics 2017;7:4118-34.DOIPubMedPMC
107. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 2010;17:F19-36.DOIPubMed
108. Cai J, Yang C, Yang Q, Ding H, Jia J, et al. Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis 2013;2:e75.DOIPubMedPMC
109. Xiao M, Cai J, Cai L, Jia J, Xie L, et al. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair. J Ovarian Res 2017;10:24.DOIPubMedPMC
110. Zhao HM, Wei W, Sun YH, Gao JH, Wang Q, et al. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells. Tumour Biol 2015;36:6867-73.DOIPubMed
111. Sun C, Li N, Yang Z, Zhou B, He Y, et al. MiR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl Cancer Inst 2013;105:1750-8.DOIPubMed
112. Pink RC, Samuel P, Massa D, Caley DP, Brooks SA, et al. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol Oncol 2015;137:143-51.DOIPubMed
113. Jin AH, Wei ZL. Molecular mechanism of increased sensitivity of cisplatin to ovarian cancer by inhibition of microRNA-23a expression. Int J Clin Exp Med 2015;8:13329-34.PubMedPMC
114. Samuel P, Pink RC, Caley DP, Currie JM, Brooks SA, Carter DR. Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells. Tumour Biol 2016;37:2565-73.DOIPubMed
115. Lv T, Song K, Zhang L, Li W, Chen Y, et al. MiRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1. Biochem Cell Biol 2018;96:663-71.DOIPubMed
116. Li B, Chen H, Wu N, Zhang WJ, Shang LX. Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance. Int J Gynecol Cancer 2014;24:1381-8.DOIPubMed
117. Yang C, Cai J, Wang Q, Tang H, Cao J, et al. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol 2012;124:325-34.DOIPubMed
118. Zhao H, Liu S, Wang G, Wu X, Ding Y, et al. Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer. Oncol Rep 2015;33:591-8.DOIPubMed
119. Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, et al. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol 2014;8:874-83.DOIPubMedPMC
120. Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, et al. MicroRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol 2013;8:1156-62.DOIPubMedPMC
121. Miles GD, Seiler M, Rodriguez L, Rajagopal G, Bhanot G. Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Res Notes 2012;5:164.DOIPubMedPMC
122. Jiang Y, Jiang J, Jia H, Qiao Z, Zhang J. Recovery of miR-139-5p in ovarian cancer reverses cisplatin resistance by targeting C-Jun. Cell Physiol Biochem 2018;51:129-41.DOIPubMed
123. Fabrizio FP, Sparaneo A, Trombetta D, Muscarella LA. Epigenetic versus genetic deregulation of the KEAP1/NRF2 axis in solid tumors: focus on methylation and noncoding RNAs. Oxid Med Cell Longev 2018;2018:2492063.DOIPubMedPMC
124. van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, et al. MiR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 2013;32:4284-93.DOIPubMed
125. Deng Y, Zhao F, Hui L, Li X, Zhang D, et al. Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression. J Ovarian Res 2017;10:50.DOIPubMedPMC
126. Zhao H, Bi T, Qu Z, Jiang J, Cui S, et al. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma. Oncol Rep 2014;32:1003-12.DOIPubMed
127. Zhou Y, Chen Q, Qin R, Zhang K, Li H. MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells. Tumour Biol 2014;35:12369-78.DOIPubMed
128. Arrighetti N, Cossa G, De Cecco L, Stucchi S, Carenini N, et al. PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells. Toxicol Appl Pharmacol 2016;310:9-19.DOIPubMed
129. Chen W, Zeng W, Li X, Xiong W, Zhang M, et al. MicroRNA-509-3p increases the sensitivity of epithelial ovarian cancer cells to cisplatin-induced apoptosis. Pharmacogenomics 2016;17:187-97.DOIPubMed
130. Chen W, Du J, Li X, Su J, Huang Y, et al. MiR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes. Pharmacogenomics 2017;18:1671-82.DOIPubMed
131. Niu L, Ni H, Hou Y, Du Q, Li H. MiR-509-3p enhances platinum drug sensitivity in ovarian cancer. Gene 2019;686:63-7.DOIPubMed
132. Zhang J, Liu L, Sun Y, Xiang J, Zhou D, et al. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression. Oncotarget 2016;7:26516-34.DOIPubMedPMC
133. Ottevanger PB. Ovarian cancer stem cells more questions than answers. Semin Cancer Biol 2017;44:67-71.DOIPubMed
134. Wei Z, Liu Y, Wang Y, Zhang Y, Luo Q, et al. Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer. Med Oncol 2016;33:126.DOIPubMedPMC
135. Fuss JO, Tainer JA. XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase. DNA Repair (Amst) 2011;10:697-713.DOIPubMedPMC
136. Zhao H, Yu X, Ding Y, Zhao J, Wang G, et al. MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2. Oncotarget 2016;7:53254-68.DOIPubMedPMC
137. Bruchim I, Werner H. Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert Opin Ther Targets 2013;17:307-20.DOIPubMed
138. Zhang Y, Huang S, Guo Y, Li L. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R. Biomed Pharmacother 2018;106:1357-63.DOIPubMed
139. Stuckrath I, Rack B, Janni W, Jager B, Pantel K, et al. Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients. Oncotarget 2015;6:13387-401.DOIPubMedPMC
140. Wilczyński M, Zytko E, Szymanska B, Dzieniecka M, Nowak M, et al. Expression of miR-146a in patients with ovarian cancer and its clinical significance. Oncol Lett 2017;14:3207-14.DOIPubMedPMC
141. Benson EA, Skaar TC, Liu Y, Nephew KP, Matei D. Carboplatin with decitabine therapy, in recurrent platinum resistant ovarian cancer, alters circulating mirnas concentrations: a pilot study. PLoS One 2015;10:e0141279.DOIPubMedPMC
142. Schwarzenbach H. The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer. Expert Rev Mol Diagn 2015;15:1159-69.DOIPubMed
143. Kuhlmann JD, Chebouti I, Kimmig R, Buderath P, Reuter M, et al. Extracellular vesicle-associated miRNAs in ovarian cancer - design of an integrated NGS-based workflow for the identification of blood-based biomarkers for platinum-resistance. Clin Chem Lab Med 2018; doi: 10.1515/cclm-2018-1048.DOIPubMed
144. Wiedemeyer WR, Beach JA, Karlan BY. Reversing platinum resistance in high-grade serous ovarian carcinoma: targeting BRCA and the homologous recombination system. Front Oncol 2014;4:34.DOIPubMedPMC
145. Fell VL, Schild-Poulter C. The Ku heterodimer: function in DNA repair and beyond. Mutat Res Rev Mutat Res 2015;763:15-29.DOIPubMed
146. Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, et al. Platinum and PARP inhibitor resistance due to overexpression of MicroRNA-622 in BRCA1-mutant ovarian cancer. Cell Rep 2016;14:429-39.DOIPubMedPMC
147. Yu X, Chen Y, Tian R, Li J, Li H, et al. MiRNA-21 enhances chemoresistance to cisplatin in epithelial ovarian cancer by negatively regulating PTEN. Oncol Lett 2017;14:1807-10.DOIPubMedPMC
148. Chan JK, Blansit K, Kiet T, Sherman A, Wong G, et al. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol Oncol 2014;132:739-44.DOIPubMed
149. Liu S, Fang Y, Shen H, Xu W, Li H. Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis. Acta Biochim Biophys Sin (Shanghai) 2013;45:756-62.DOIPubMed
150. Liu W, Wang S, Zhou S, Yang F, Jiang W, et al. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells. Mol Biosyst 2017;13:2268-76.DOIPubMed
151. Yu PN, Yan MD, Lai HC, Huang RL, Chou YC, et al. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int J Cancer 2014;134:542-51.DOIPubMed
152. Han X, Zhen S, Ye Z, Lu J, Wang L, et al. A feedback loop between miR-30a/c-5p and DNMT1 mediates cisplatin resistance in ovarian cancer cells. Cell Physiol Biochem 2017;41:973-86.DOIPubMed
153. Liu J, Wu X, Liu H, Liang Y, Gao X, et al. Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines. Oncol Lett 2016;12:2065-70.DOIPubMedPMC
154. Srivastava AK, Han C, Zhao R, Cui T, Dai Y, et al. Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells. Proc Natl Acad Sci U S A 2015;112:4411-6.DOIPubMedPMC
155. Liu L, Guo J, Yu L, Cai J, Gui T, et al. MiR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer. Tumour Biol 2014;35:12619-26.DOIPubMed
156. Li H, Xu H, Shen H, Li H. MicroRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells. Oncol Lett 2014;7:183-8.DOIPubMedPMC
157. Rao YM, Shi HR, Ji M, Chen CH. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells. J Huazhong Univ Sci Technolog Med Sci 2013;33:567-72.DOIPubMed
158. Kong F, Sun C, Wang Z, Han L, Weng D, et al. MiR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technolog Med Sci 2011;31:543.DOIPubMed
159. Li N, Yang L, Wang H, Yi T, Jia X, et al. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells. PLoS One 2015;10:e0128886.DOIPubMedPMC
160. Zhang X, Huang L, Zhao Y, Tan W. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly. Acta Biochim Biophys Sin (Shanghai) 2013;45:995-1001.DOIPubMed
161. Yang L, Li N, Wang H, Jia X, Wang X, et al. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep 2012;28:592-600.DOIPubMed
162. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, et al. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008;111:478-86.DOIPubMed
163. Zong C, Wang J, Shi TM. MicroRNA 130b enhances drug resistance in human ovarian cancer cells. Tumour Biol 2014;35:12151-6.DOIPubMed
164. Chen S, Jiao JW, Sun KX, Zong ZH, Zhao Y. MicroRNA-133b targets glutathione S-transferase pi expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Drug Des Devel Ther 2015;9:5225-35.DOIPubMedPMC
165. Li X, Chen W, Jin Y, Xue R, Su J, et al. MiR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes. Biochem Pharmacol 2019;161:98-112.DOIPubMed
166. Xu M, Xiao J, Chen M, Yuan L, Li J, et al. MiR1495p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway. Int J Oncol 2018;52:815-27.DOIPubMedPMC
167. He J, Yu JJ, Xu Q, Wang L, Zheng JZ, et al. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy. Autophagy 2015;11:373-84.DOIPubMedPMC
168. Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 2014;33:378-86.DOIPubMed
169. Sun KX, Jiao JW, Chen S, Liu BL, Zhao Y. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1. J Ovarian Res 2015;8:80.DOIPubMedPMC
170. Zhu X, Shen H, Yin X, Long L, Xie C, et al. MiR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene 2016;35:323-32.DOIPubMed
171. Cui Y, Wu F, Tian D, Wang T, Lu T, et al. MiR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8. Oncol Rep 2018;39:1649-57.DOIPubMedPMC
172. Wang Z, Ting Z, Li Y, Chen G, Lu Y, et al. MicroRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin. Oncol Lett 2013;6:789-94.DOIPubMedPMC
173. Liu MX, Siu MK, Liu SS, Yam JW, Ngan HY, et al. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget 2014;5:944-58.DOIPubMedPMC
174. Zhu X, Shen H, Yin X, Long L, Chen X, et al. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells. Oncotarget 2017;8:39154-66.DOIPubMedPMC
175. Lin M, Xia B, Qin L, Chen H, Lou G. S100A7 regulates ovarian cancer cell metastasis and chemoresistance through MAPK signaling and is targeted by miR-330-5p. DNA Cell Biol 2018;37:491-500.DOIPubMed
176. Liu R, Guo H, Lu S. MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2. Cancer Med 2018;7:4598-609.DOIPubMedPMC
177. Cao L, Wan Q, Li F, Tang CE. MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. BMB Rep 2018;51:456-61.PubMedPMC
178. Ye G, Fu G, Cui S, Zhao S, Bernaudo S, et al. MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci 2011;124:359-68.DOIPubMed
179. Zou J, Liu L, Wang Q, Yin F, Yang Z, et al. Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1. Am J Transl Res 2017;9:1357-68.PubMedPMC
180. Wu H, Xiao Z, Zhang H, Wang K, Liu W, et al. MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3. Anticancer Drugs 2014;25:799-809.DOIPubMed
181. Tian J, Xu YY, Li L, Hao Q. MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2. Am J Transl Res 2017;9:1127-38.PubMedPMC
182. Xu S, Fu GB, Tao Z, OuYang J, Kong F, et al. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget 2015;6:26457-71.DOIPubMedPMC
183. van Jaarsveld MT, van Kuijk PF, Boersma AW, Helleman J, van IWF, et al. MiR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. Mol Cancer 2015;14:196.DOIPubMedPMC
184. Qin X, Sun L, Wang J. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway. Cell Biol Int 2017;41:1110-8.DOIPubMed
185. Wu DD, Li XS, Meng XN, Yan J, Zong ZH. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1. Tumour Biol 2016;37:10499-506.DOIPubMed
186. Brozovic A, Duran GE, Wang YC, Francisco EB, Sikic BI. The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells. Mol Oncol 2015;9:1678-93.DOIPubMedPMC
187. Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U S A 2013;110:9845-50.DOIPubMedPMC
Cristiana Lo Nigro et al., Cancer Drug Resistance, 2019
Natarajan Aravindan et al., Cancer Drug Resistance, 2019
Diletta Francesca Squarzanti et al., Journal of Cancer Metastasis and Treatment, 2019
Constance Gaya Cremers et al., Cancer Drug Resistance, 2019
Mireia Cruz De los Santos et al., Cancer Drug Resistance, 2019
Matthew Ho et al., Journal of Cancer Metastasis and Treatment, 2019
Natarajan Aravindan et al., Cancer Drug Resistance, 2019
Lauren K. Meyer et al., Cancer Drug Resistance, 2019
Kaouthar Bouzinab et al., Cancer Drug Resistance, 2019
Cathy W. Levenson et al., Cancer Drug Resistance, 2019